Login to Your Account



New Platform Brings Vivalis €150M Antibody Sanofi Deal

By Cormac Sheridan


Wednesday, June 9, 2010
Six months after acquiring the Humalex antibody platform from Humalys, Vivalis SA secured its first license agreement for the technology, a wide-ranging alliance in infectious disease with Paris-based Sanofi-Aventis Group. Nantes, France-based Vivalis is receiving an up-front payment of €3 million (US$3.6 million), plus another potential €35 million in milestones per indication, as well as royalties on product sales. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription